Immungenetics AG

Developing effective treatments for devastating diseases: Neurodegeneration, Inflammation, Mitochondrial Dysfunctions, Aging


Guido Hillebrands


Guido co-founded inno group in 1991, which he quickly grew and internationalized into five countries. A visionary strategist, Guido realized that there was a need to align public sector investment into basic research with the technological innovation needed by industry. He then designed and implemented the most successful German start-up initiative (KEIM) that led to the formation of more than 200 companies. His work on developing an Innovation Strategy for a region of Austria led to him managing 250 mln USD in public investment funds and was recognized as the most innovative region by the President of the European Commission. Over the last 25 years, Guido has led innovation programmmes with more than 40 renowned public institutions across Europe and has built an impressive portfolio of start-up companies many of which comprise part of the current portfolio.


Antonio Martinez Arbizu

Chief Executive Officer

CEO Antonio Martinez Arbizu is a seasoned serial entrepreneur dedicated to growing companies based on cutting-edge research from public research institutions. Linked to Immungenetics since its beginnings, Antonio has brought the company to the clinical stage. With a background in Electrical and Communications Engineering, Antonio is an expert in IPR management and has in-depth knowledge of a vast array of technological and life science fields. He joined the company's major shareholder innoveas in 1994. Initially advising governments and universities on the creation of start-ups, he structured and founded several seed and venture capital funds as well as business angel networks, endowments and trusts across Europe, working with many talented entrepreneurs and executives to launch, grow and internationalize over 60 innovative enterprises. A highly experienced technology, financial and market expert, Antonio has started and directed some fifteen technology companies from research results into early revenues. He sits on the Boards of several innoveas companies.


Prof. Dr. Dr. Jens Pahnke, M.D., Ph.D., E.F.N.

Co-founder & Lead Researcher

Jens Pahnke studied Medicine and Molecular Biology at the University of Greifswald (Germany). He has held several Professorships and leadership positions including at the University of Rostock (Germany) and the Neurodegeneration Research Lab (NRL) at the University of Magdeburg (Germany) including stages in Zürich and Oxford. Jens is currently Professor at the University of Oslo (Norway) and the Head of the Department of Neuropathology at the Oslo University Hospital (OUS, Helseforeningen SØ), and Professor at the LIED University of Lübeck and the Leibniz Institute for Plant Biochemistry in Halle/Saale (Germany). His research covers basic and translational research for Alzheimer’s disease (AD) and other neurodegenerative disorders. His scientific discovery on uncovering the importance of specific ABC transporters for the clearance of toxic peptides from the Brain through the blood brain barrier has lead to Immungenetics pursuing an innovative new treatment option and their utilization in diagnostics of Alzheimer’s disease. He became a Specialist in Neuropathology in 2008. As Professor at the University in Rostock 2005-2012 he was responsible for the DGM Muscle Centre in Mecklenburg-Western Pomerania. He now runs the neuropath diagnostics for South-East Norway and the Neuropathology Reference Center for Norway.


Prof. Dr. med. Saleh Ibrahim

Co-founder & Lead Researcher

After finishing his medical training in Egypt, Saleh Ibrahim has been studying several aspects of autoimmunity for the last 20 years with a primary focus on genetics. At the Department of Bacteriology and Immunology, Helsinki University (Finland), where he obtained his doctoral degree in Immunology, he studied the potential influence of bacterial surface proteins on the B cell repertoire. During that period, he received his basic training in molecular immunology. He then moved to the Department of Molecular Biology, Princeton University (USA), in 1993 where he studied mechanisms of B cell tolerance. During that time he received his training in molecular genetics. In 1996 he moved to the University of Rostock, Germany, where he spent more than 10 years establishing an independent research group. There he developed novel mouse models to study the genetics of autoimmune diseases. In 2008 he moved to the University of Lübeck as a professor with a research focus on the genetics of skin inflammatory diseases. Saleh leads Immungenetics' R&D programme on mitochondrial dysfunctions, inflammation and autoimmunity.